<DOC>
	<DOCNO>NCT00741481</DOCNO>
	<brief_summary>Study hypothesis : early decrease fdg-pet measure SUV max 1 cycle chemotherapy accurately predict response chemotherapy assess conventional radiology 3 cycle chemotherapy . FDG-PET image do J0 J14 new line chemotherapy treatment metastatic colorectal cancer . SUV max record delta SUVmax compare result conventional radiological evaluation 3 course chemotherapy . Results also compare time disease progression .</brief_summary>
	<brief_title>PET Evaluation Response After 1 Course Chemotherapy Predictor Treatment Outcome .</brief_title>
	<detailed_description>statistical hypothesis : Sample size calculation FDG-PET metastatic patient . In paper Cascini et al . [ 1 ] , 18 patient TRG response ( TRG = Tumor Regression Grade ) 15 patient response . SUV mean measure baseline day 12 33 patient . All 33 patient show reduction SUV-mean baseline day 12 . The median reduction SUV-mean 63 % ( mean 66 % ) respond tumor 22 % ( mean 22 % ) non respond tumor . Using cutoff level 52 % perfect accuracy could obtain , i.e . respond tumor SUV-mean reduction high 52 % non respond tumor SUV-mean reduction lower 52 % . ( Standard deviation SUV-mean reduction 25 . ) All 33 patient show also reduction SUV-max baseline day 12 . The median reduction SUV-max 62 % respond tumor 28 % non responding tumor . ( No information mean standard deviation SUV-max available [ 1 ] . ) Based data SUV-mean power calculation base Wilcoxon test : In order demonstrate absolute difference mean ΔSUV-mean 44 % respond non respond patient , estimate standard deviation 25 , use 35 patient ( 50 % response , 50 % response ) , significance level 5 % , obtain power 0.98 . For SUV-max , assume difference mean similar difference median , i.e . 34 % standard deviation similar one SUV-mean , i.e . 25 , obtain power 0.93 If , safe , little bit less optimistic estimate difference mean ΔSUV-max respond non responding tumor would little low [ 1 ] : 35 % , standard deviation little bit high : 30 , need 40 patient power 0.90 Référence 1 : Cascini GL , Avallone A , Delrio P , Guida C , Tatangelo F , Marone P et al . : F-18-FDG PET early predictor pathologic tumor response preoperative radiochemotherapy locally advanced rectal cancer . Journal Nuclear Medicine 2006 , 47 : 1241-1248 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>advanced colorectal cancer evaluable disease sign informed consent cancer lifethreatening condition unwillingness inability sign inform consent active cerebral metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>fdg pet</keyword>
	<keyword>response evaluation</keyword>
</DOC>